Mac Armstrong Sells 3,500 Shares of Palomar (NASDAQ:PLMR) Stock

Palomar Holdings, Inc. (NASDAQ:PLMR) CEO Mac Armstrong sold 3,500 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $112.96, for a total value of $395,360.00. Following the completion of the sale, the chief executive officer directly owned 329,388 shares of the company’s stock, valued at $37,207,668.48. This trade represents a 1.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mac Armstrong also recently made the following trade(s):

• On Thursday, May 21st, Mac Armstrong sold 3,500 shares of Palomar stock. The shares were sold at an average price of $114.39, for a total transaction of $400,365.00.
• On Tuesday, April 21st, Mac Armstrong sold 3,500 shares of Palomar stock. The stock was sold at an average price of $130.77, for a total transaction of $457,695.00.
• On Wednesday, April 15th, Mac Armstrong sold 3,197 shares of Palomar stock. The stock was sold at an average price of $129.46, for a total transaction of $413,883.62.

Palomar Stock Performance

NASDAQ:PLMR opened at $117.84 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 0.49 and a quick ratio of 0.49. The firm has a market capitalization of $3.12 billion, a price-to-earnings ratio of 16.41 and a beta of 0.44. The company’s 50-day moving average is $115.53 and its two-hundred day moving average is $122.37. Palomar Holdings, Inc. has a 1-year low of $100.81 and a 1-year high of $156.55.

Palomar (NASDAQ:PLMR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.17 by $0.14. The business had revenue of $278.94 million during the quarter, compared to the consensus estimate of $557.79 million. Palomar had a net margin of 20.11% and a return on equity of 22.62%. The business’s revenue was up 59.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.87 EPS. Analysts forecast that Palomar Holdings, Inc. will post 9.14 EPS for the current year.

More Palomar News

Here are the key news stories impacting Palomar this week:

• Positive Sentiment: Zacks Research raised its FY2026 earnings estimate for Palomar to $9.87 per share from $8.99, which suggests stronger profit expectations for the next fiscal year. Palomar Holdings analyst update
• Positive Sentiment: The company was highlighted as a property & casualty insurer that may be better positioned to handle the 2026 hurricane season, supporting the bullish case for its specialty insurance model. Article about P&C insurers poised to weather hurricane season
• Neutral Sentiment: Zacks Research maintained a Hold rating, which signals analysts see limited near-term upside even though some earnings estimates improved. Palomar Holdings analyst rating
• Neutral Sentiment: CEO Mac Armstrong sold 3,500 shares in a pre-arranged Rule 10b5-1 transaction, which is a routine insider sale but can still weigh on sentiment. SEC insider filing
• Negative Sentiment: Zacks trimmed some future earnings forecasts, including Q3 2026 and FY2027, which may have dampened enthusiasm around Palomar’s longer-term growth trajectory. Palomar Holdings analyst update

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Wall Street Zen downgraded Palomar from a “buy” rating to a “hold” rating in a research report on Sunday, March 1st. Piper Sandler cut their price objective on Palomar from $151.00 to $132.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Weiss Ratings upgraded shares of Palomar from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 18th. Keefe, Bruyette & Woods decreased their target price on shares of Palomar from $186.00 to $159.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Palomar from $160.00 to $150.00 and set an “overweight” rating for the company in a research note on Tuesday, May 26th. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $147.75.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada raised its holdings in shares of Palomar by 49.1% in the 1st quarter. Royal Bank of Canada now owns 2,956 shares of the company’s stock valued at $406,000 after buying an additional 974 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Palomar by 5.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,427 shares of the company’s stock valued at $2,115,000 after acquiring an additional 791 shares during the period. NewEdge Advisors LLC purchased a new position in Palomar during the 1st quarter valued at about $66,000. United Services Automobile Association acquired a new position in Palomar in the 1st quarter valued at about $223,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Palomar by 11.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 72,661 shares of the company’s stock valued at $9,960,000 after purchasing an additional 7,754 shares in the last quarter. 90.25% of the stock is currently owned by hedge funds and other institutional investors.

About Palomar

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.